Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12543621 | 0.85 | DRD2 (0.37) | DRD2SLC6A4P2RX7HTR6 | |
| SCHEMBL23739994 | 0.80 | DGAT1 (0.48) | DRD2SLC6A4DGAT1GRM2 | |
| SCHEMBL2037471 | 0.80 | HTR6 (0.37) | DRD2SLC6A4P2RX7HTR6 | |
| SCHEMBL18029346 | 0.78 | DRD2 (0.40) | DRD2SLC6A4 | |
| SCHEMBL15732924 | 0.78 | DGAT1 (0.49) | DRD2SLC6A4DGAT1GRM2 | |
| SCHEMBL15745373 | 0.74 | DGAT1 (0.42) | DRD2SLC6A4DGAT1GRM2 | |
| SCHEMBL12384269 | 0.73 | SLC6A4 (0.39) | SLC6A4HTR1AGRM2 | |
| SCHEMBL28990232 | 0.73 | BACE1 (0.46) | GRM2 | |
| SCHEMBL15732940 | 0.73 | DGAT1 (0.43) | DGAT1GRM2 | |
| SCHEMBL28577320 | 0.71 | CDK4 (0.39) | DRD2SLC6A4P2RX7GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796729-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DRD2 3952/4885SLC6A4 2830/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.